AstraZeneca Finds Two More Potential Partners For Imfinzi

Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors

 
• By Alaric DeArment
  
Lung Cancer
AstraZeneca reported results at ESMO on Imfinzi combined with CD73 inhibitor oleclumab and NGK2A inhibitor monalizumab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas